Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Current Liabilities: 2014-2024

Historic Total Current Liabilities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Dec 2024 value amounting to $47.9 million.

  • Viridian Therapeutics, Inc.\DE's Total Current Liabilities rose 22.56% to $50.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.7 million, marking a year-over-year increase of 22.56%. This contributed to the annual value of $47.9 million for FY2024, which is 79.74% up from last year.
  • According to the latest figures from FY2024, Viridian Therapeutics, Inc.\DE's Total Current Liabilities is $47.9 million, which was up 79.74% from $26.6 million recorded in FY2023.
  • Viridian Therapeutics, Inc.\DE's 5-year Total Current Liabilities high stood at $47.9 million for FY2024, and its period low was $10.7 million during FY2020.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Total Current Liabilities averaged around $36.0 million, with its median value being $33.3 million (2022).
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Total Current Liabilities soared by 144.57% in 2022 and then fell by 20.13% in 2023.
  • Yearly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Total Current Liabilities stood at $10.7 million in 2020, then grew by 27.75% to $13.6 million in 2021, then skyrocketed by 144.57% to $33.3 million in 2022, then fell by 20.13% to $26.6 million in 2023, then surged by 79.74% to $47.9 million in 2024.